AUA Annual Meeting Highlights (2018): Immunotherapy in GU Cancer

An AUA survey indicated that urologists see an average of 17 patients a month with bladder cancer. While 84% of respondents felt very knowledgeable about the surgical treatment options, only 44% of them felt very knowledgeable about chemotherapy and immunotherapy options. When asked about increasing their knowledge in the area of bladder cancer 75.4% stated it was necessary to extremely necessary.

Target Audience

  • Urologists
  • Urologists in training
  • Non-physician providers involved in urology

Learning Objectives

Course 005IC: Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for the Advanced Practice Provider

At the conclusion of this CME activity, participants should be able to:

•    Describe the standard of care chemotherapy regimens for genitourinary malignancies
•    Recognize newer immunotherapy options in the treatment of genitourinary malignancies
•    Identify and manage the toxicities with relation to these agents
•    Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies

Course 019IC: Immunotherapy for the Urologist: Basic Principles, Adverse Effects & Drug Delivery

At the conclusion of this CME activity, participants should be able to:

•    Describe the new innovations in tumor immunology and new immunotherapies in order to identify the right drug for the right patient
•    Summarize the major findings in bladder and kidney cancer trials using immunotherapy
•    Define the non-immune and the immune related side effects and manage the common side effects of immunotherapy
•    Discuss the implementation of a systemic immunotherapy program in your practice, including regulatory, billing and coding for immunotherapy treatment
•    Identify predictive biomarkers of immuno-oncology treatment

Course 055IC: Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease & CRPC

At the conclusion of this CME activity, participants should be able to:

•    Counsel men with BRCA1/2 mutations, Lynch syndrome and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening
•    Understand the criteria for genetic testing of patients with prostate cancer, the gene panels available, and options for testing these men
•    Interpret results of genetic testing and relay this information to patients in order to facilitate shared decision making based on the test results
•    Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy and immunotherapy

Course 058IC: Management of Common Dilemmas in Prostate Cancer Diagnosis, Staging & Treatment

At the conclusion of this CME activity, participants should be able to:

•    Use shared decision making to test men with PSA, to decide whom to biopsy and how to biopsy
•    Understand the pros and cons of different types of biopsy and how to select men for surveillance, surgery or XRT
•    Determine the new therapies for advanced and metastatic cancer with ADT, chemotherapy and immunotherapies
•    Identify the roles of new staging PET scans

Urologic Care for the Advanced Practice Provider: Bladder Cancer: New Diagnostic Tools, Intravesical Therapies, and Management of Intravesical Drug Toxicities

At the conclusion of this CME activity, participants should be able to:

•    Recognize new tools for diagnosing and surveilling patients with non-muscle invasive bladder cancer 
•    Examine intravesical therapy options pre and post BCG failure 
•    Identify and treat toxicities associated with intravesical therapy 

Tumor Board: Bladder Cancer

At the conclusion of this CME activity, participants should be able to:

•    Identify novel immunotherapies for urothelial cancer 
•    Discuss the mechanism of action of PD-1 immunotherapy 
•    Identify current trials of perioperative immunotherapy
•    Explain the rationale for trials of PD-1 immunotherapy for patients with non-muscle invasive bladder cancer

Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Course opens: 
10/01/2018
Course expires: 
10/01/2019

Course 005IC: Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for the Advanced Practice Provider

Costas D. Lallas, MD, FACS, Course Director
Vice Chair and Professor of Urology
Thomas Jefferson University Hospital
Philadelphia, PA
Disclosures: Nothing to disclose

Anne E. Calvaresi, MSN, CRNP
Nurse Practitioner, Urologic Oncology
Thomas Jefferson University
Philadelphia, PA
Disclosures: Nothing to disclose 

Edouard J. Trabulsi, MD, FACS
Professor and Vice Chair, Department of Urology
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA
Disclosures: Nothing to disclose


Course 019IC: Immunotherapy for the Urologist: Basic Principles, Adverse Effects & Drug Delivery

Joshua Meeks, MD, PhD, Course Director
Assistant Professor, Department of Urology
Northwestern University 
Evanston, IL
Disclosures: National Comprehensive Cancer Network- Prostate Cancer Guidelines Committee: Other; Veteran's Health Administration: Scientific Study or Trial; Merck: Scientific Study or Trial

Peter Black, MD, FACS, FRCSC
Oncologist, Vancouver General Hospital
Research Scientist, Vancouver Prostate Centre
Professor, Department of Urologic Sciences
University of British Columbia
Vancouver, British Columbia
Disclosures: GenomeDx Biosciences Inc: Consultant or Advisor, Scientific Study or Trial; Janssen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Amgen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Sitka: Consultant or Advisor; AbbVie: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; PLOS ONE: Health Publishing; BMC Urology: Health Publishing; Merck: Consultant or Advisor; iProgen: Scientific Study or Trial; Bayer: Consultant or Advisor; Biosyent: Consultant or Advisor; RedLeaf Medical: Meeting Participant or Lecturer; Biocancell: Consultant or Advisor; Roche/Genentech: Consultant or Advisor, Scientific Study or Trial; World Journal of Urology: Health Publishing; Urologic Oncology:     Health Publishing; Bladder Cancer: Health Publishing

Terence Friedlander, MD
Chief, Hematology-Oncology
Zuckerberg San Francisco General
Associate Clinical Professor, Division of Hematology/Oncology
University of California, San Francisco
San Francisco, CA
Disclosures: Nothing to disclose

Neal Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center 
Atlantic Urology Clinics 
Myrtle Beach, SC 
Disclosures: GP Pharma: Consultant or Advisor; Astellas: Consultant or Advisor; Dendreon: Consultant or Advisor; Janssen: Consultant or Advisor; Bayer: Consultant or Advisor; Myriad: Consultant or Advisor; Pfizer: Consultant or Advisor, Scientific Study or Trial; Genomic Health: Consultant or Advisor; MDxHealth: Consultant or Advisor; Tolmar: Consultant or Advisor, Scientific Study or Trial; Moivant: Consultant or Advisor, Scientific Study or Trial; Spectrum: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Consultant or Advisor, Scientific Study or Trial

Brian Shuch, MD
Associate Professor, Urology and Radiology and Biomedical Imaging
Director, Genitourinary Cancer Genetics and Prevention Program
Yale School of Medicine
New Haven, CT
Disclosures: Nothing to disclose

Kelly Stratton, MD
Assistant Professor, Urologic Oncology
Adjunct Assistant Professor, Medical Oncology 
Stephenson Cancer Center, University of Oklahoma 
Oklahoma City, OK
Disclosures: Ebix: Other; Bayer Corporation: Consultant or Advisor; Oakstone: Other

Robert Svatek, MD
Associate Professor
Chief, Division of Urologic Oncology
UT Health Science Center 
San Antonio, TX
Disclosures: Japanese BCG Laboratories: Scientific Study or Trial; Rapamycin Holdings: Consultant or Advisor


Course 055IC: Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease & CRPC

Todd M. Morgan, MD, Course Director
Associate Professor, Urology
University of Michigan 
Ann Arbor, MI
Disclosures: Visible Health, Inc: Leadership Position, Owner, Product Development; Myriad Genetics: Scientific Study or Trial; GenomeDx: Scientific Study or Trial; MDxHealth: Scientific Study or Trial

Leonard Gomella, MD, FACS
Chair, Department of Urology
Director, Kimmel Cancer Center Network 
Thomas Jefferson University
Philadelphia, PA
Disclosures: Astellas: Consultant or Advisor; Janssen: Consultant or Advisor; Wolters Kluwer: Health Publishing; McGraw Hill: Health Publishing; Merck Manual: Health Publishing; Canadian Journal of Urology: Health Publishing; MDxHealth: Consultant or Advisor; Merck Pharmaceuticals:  Consultant or Advisor; Bayer:  Consultant or Advisor

Heather H. Cheng, MD, PhD
Assistant Professor, Medical Oncology 
University of Washington
Seattle, WA
Disclosures: Nothing to disclose


Course 058IC: Management of Common Dilemmas in Prostate Cancer Diagnosis, Staging & Treatment

Gerald L. Andriole, Jr., MD, Course Director
Chief, Division of Urologic Surgery
Professor, Urologic Surgery
Vice Chair, Department of Surgery
Washington University
St. Louis, MO
Disclosures: Augmenix:  Consultant or Advisor, Other; Medivation: Scientific Study or Trial; Blue Earth Diagnostics: Scientific Study or Trial; Progenics: Scientific Study or Trial; Tolmar Pharmaceuticals: Consultant or Advisor; 3D Biopsy: Consultant or Advisor; Boston Scientific: Consultant or Advisor; American Urological Association: Meeting Participant or Lecturer; Endourological Society: Meeting Participant or Lecturer

Anthony D’Amico, MD, PhD
Chair and Chief, Division of Genitourinary Radiation Oncology
Dana-Farber Cancer Institute and Brigham and Women’s Hospital
Boston, MA
Disclosures: Nothing to disclose

Adam Kibel, MD
Chief, Division of Urology
Brigham and Women’s Hospital and Dana-Farber Cancer Institute
Professor of Surgery, Urology
Harvard Medical School
Boston, MA
Disclosures: Profound: Consultant or Advisor; Janssen: Consultant or Advisor

Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Professor, Department of Medicine and Urology
Tulane Medical School
New Orleans, LA
Disclosures: sanofi-aventis: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Johnson & Johnson: Consultant or Advisor, Scientific Study or Trial; Oncogenex: Consultant or Advisor; Bellicum: Consultant or Advisor; Bayer: Consultant or Advisor, Scientific Study or Trial; Bristol-Myers Squibb: Consultant or Advisor; Innocrin: Consultant or Advisor, Scientific Study or Trial; NRG: Leadership Position; Bavarian-Nordic: Consultant or Advisor; AstraZeneca: Consultant or Advisor; Squibb: Consultant or Advisor; Celgene: Consultant or Advisor; Dendreon: Consultant or Advisor; EMD Serono: Consultant or Advisor; Endocyte: Consultant or Advisor, Scientific Study or Trial

Eric H. Kim, MD, Author
Assistant Professor, Urologic Surgery 
Washington University School of Medicine
St. Louis, MO
Disclosures: Nothing to disclose 


Urologic Care for the Advanced Practice Provider: Bladder Cancer: New Diagnostic Tools, Intravesical Therapies, and Management of Intravesical Drug Toxicities

Heather Schultz, RN, MSN, NP-C, Course Co-Director
Nurse Practitioner, Department of Urology
University of North Carolina at Chapel Hill, 
Chapel Hill, NC
Disclosures: SUNA: Meeting Participant or Lecturer

Kenneth Mitchell, MPAS, PA-C, Course Co-Director
Physician Assistant
Meharry Medical College
Nashville, TN
Disclosures: Nothing to disclose

Michael A. O’Donnell, MD
Director and Professor, Urologic Oncology
University of Iowa Carver College of Medicine
Iowa City, IA
Disclosures: Photocure: Scientific Study or Trial; Telesta: Consultant or Advisor; Roche/Genentech: Scientific Study or Trial; Medical Enterprises: Consultant or Advisor, Scientific Study or Trial; Theralase: Consultant or Advisor, Investment Interest; Spectrum Pharmaceuticals: Consultant or Advisor; Fidia Pharmaceuticals: Consultant or Advisor; Abbott Molecular: Scientific Study or Trial


Tumor Board: Bladder Cancer

Eila Skinner, MD, Moderator
Chair and Professor, Department of Urology
Stanford University
Stanford, CA
Disclosures: Genentech: Scientific Study or Trial

Yair Lotan, MD, Panelist
Chief, Urologic Oncology
Professor, Department of Urology
UT Southwestern
Dallas, TX
Disclosures: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial

Seth Lerner, MD, FACS, Panelist
Chair, Urologic Oncology
Professor, Department of Urology
Baylor College of Medicine
Houston, TX
Disclosures: Endo Pharmaceuticals: Scientific Study or Trial; FKD: Scientific Study or Trial; UroGen: Consultant or Advisor; Biocancell: Consultant or Advisor; Vaxxion: Consultant or Advisor; Nucleix: Consultant or Advisor; Viventia: Scientific Study or Trial; UpToDate: Health Publishing; Bladder Cancer Journal: Health Publishing

Neha Vapiwala, MD, Panelist
Vice Chair and Associate Professor, Department of Radiation Oncology
Assistant Dean of Students
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Disclosures: Nothing to disclose

Terence Friedlander, MD, Panelist
Associate Professor
University of California, San Francisco
San Francisco, CA
Disclosures: Genentech: Consultant or Advisor; Foundations Medicine: Consultant or Advisor; Pfizer: Consultant or Advisor

Estimated time to complete this activity: 1.25 hours 
Release Date: October 2018
Expiration Date: October 31, 2019

Accreditation Statement: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Planners:

Manoj Monga, MD, FACS
Director, Center for Endourology & Stone Disease
Cleveland Clinic
Cleveland, OH
Disclosures: Fortec: Other

Victor W. Nitti, MD
Professor, Department of Urology
Professor, Department of Obstetrics and Gynecology
Director, Female Pelvic Medicine and Reconstructive Surgery
Vice Chair, Department of Urology
New York University Langone Medical Center
New York, NY
Disclosures: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Medtronic: Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest 

Michael Abern, MD
Assistant Professor, Urology
Director, Urologic Oncology 
University of Illinois at Chicago
Chicago, IL
Disclosures: Department of Defense Prostate Cancer Research Program: Scientific Study or Trial, Consultant or Advisor

Acknowledgements

The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

  • AstraZeneca
  • Genentech
  • Merck & Co., Inc.

American Urological Association Education & Research, Inc. ensures that all educational activities are developed and implemented independent of the control and/or influence of any commercial interests (ACCME: SCS1).

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
•    Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education COI Review Work Group or its subgroup
•    Limit content to evidence with no recommendations
•    Introduction of a debate format with an unbiased moderator (point-counterpoint)
•    Inclusion of moderated panel discussion
•    Publication of a parallel or rebuttal article for an article that is felt to be biased
•    Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
•    Divestiture of the relationship by faculty

Evidence-Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
 
AUA Privacy and Confidentiality Policy: Access the AUA Privacy and Confidentiality Policy online at www.auanet.org/education/confidentiality-statement.cfm.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation

Accreditation Period

Course opens: 
10/01/2018
Course expires: 
10/01/2019
Please login or register to take this course.